Lipella Pharmaceuticals (LIPO) versus Its Competitors Financial Contrast

Lipella Pharmaceuticals (NASDAQ:LIPO) is one of 1,048 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Lipella Pharmaceuticals to related businesses based on the strength of its analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Valuation & Earnings

This table compares Lipella Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lipella Pharmaceuticals	$450,000.00	-$4.62 million	-0.62
Lipella Pharmaceuticals Competitors	$2.54 billion	$150.53 million	-5.14

Lipella Pharmaceuticals’ rivals have higher revenue and earnings than Lipella Pharmaceuticals. Lipella Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lipella Pharmaceuticals and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0	0	1	0	3.00
Lipella Pharmaceuticals Competitors	7607	20882	48486	1193	2.55

Lipella Pharmaceuticals currently has a consensus price target of $16.00, suggesting a potential upside of 508.37%. As a group, “Pharmaceutical preparations” companies have a potential upside of 72.50%. Given Lipella Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Lipella Pharmaceuticals is more favorable than its rivals.

Profitability

This table compares Lipella Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-882.82%	-192.33%	-154.24%
Lipella Pharmaceuticals Competitors	-3,620.37%	-274.65%	-33.65%

Volatility and Risk

Lipella Pharmaceuticals has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals’ rivals have a beta of 0.79, meaning that their average share price is 21% less volatile than the S&P 500.

Summary

Lipella Pharmaceuticals beats its rivals on 8 of the 13 factors compared.

Lipella Pharmaceuticals Company Profile

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.